Intuitive’s E-100 generator and SynchroSeal gets the FDA clearance
Category: #health  By Pankaj Singh  Date: 2019-11-27
  • share
  • Twitter
  • Facebook
  • LinkedIn

Intuitive’s E-100 generator and SynchroSeal gets the FDA clearance

Intuitive, a US-based developer, manufacturer, and marketer of the robotic products designed to improve clinical results of patients through robot-assisted surgeries, reportedly announced that two of its technologies for its da Vinci surgical systems received FDA clearance.

E-100 generator and SynchroSeal instrument are the two new technologies of the company. E-100 generator is the company’s first internally designed robotic generator to support two crucial instruments on the da Vinci Xi™ and X® systems. The other instrument, SynchroSeal instrument provides improved capabilities in the field of general surgery.    

Senior Vice President and General Manager for Instruments and Accessories, Intuitive, Bob DeSantis stated that the company is thrilled to get the FDA clearance, and offering surgeons an extra tool for the Xi and X da Vinci platforms.

DeSantis further added that the company developed the E-100 generator and SynchroSeal to assist surgeons in quickly sealing and transecting vessels and tissues, enabling an efficient technique.

The E-100 is the company’s first generator and is provided as an upgrade to power SynchroSeal and Vessel Sealer Extend. SynchroSeal would allow a surgeon to perform rapid single-step sealing and transection using a single pedal press.  

SynchroSeal instrument utilizes advanced bipolar energy through its raised cut electrode for tissue transection. It then cools down quickly allowing surgeons to move on to the further step. SynchroSeal provides improved versatility to the Energy portfolio of da Vinci through its rapid sealing cycle, wristed articulation, and refined curved jaw.   

There are multiple models of the Intuitive’s da Vinci surgical system. These systems are built to help surgeons in performing minimally invasive surgery. They provide surgeons a magnified view, high-definition 3D vision, as well as computer and robotic assistance.

These systems utilize specialized instrumentation, which includes wristed instruments such as scissors, forceps and scalpels and a miniaturized surgical camera. These instruments are designed to help surgeons with precise reconstruction and dissection inside the body.

Earlier in July, the company acquired the robotic endoscopic business of Schölly Fiberoptic. The acquisition integrated Schölly’s robotic endoscope production line and two Schölly sites into Intuitive’s business.

 

Source credit: https://www.biospace.com/article/releases/u-s-fda-clears-synchroseal-and-e-100-generator-for-da-vinci-x-xi-platforms/



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

GE Healthcare Life Sciences & ASLS unite to advance 3D biofabrication
GE Healthcare Life Sciences & ASLS unite to advance 3D biofabrication
By Pankaj Singh

 

  • The alliance is aimed at personalizing regenerative tissue manufacturing processes
  • Vascularized printed cells are set to pave the way for more complex biolog...

Hummingbird Bio secures $19M to expand antibody therapeutics portfolio
Hummingbird Bio secures $19M to expand antibody therapeutics portfolio
By Pankaj Singh

Hummingbird Bioscience, an advanced biotherapeutics company, recently announced it has raised USD 19 million in a Series B funding round. Apparently, the financing round was co-led by GNTech Venture Capital and Mirae A...

Acadia announces positive results of Phase 3 trial to treat psychosis
Acadia announces positive results of Phase 3 trial to treat psychosis
By Pankaj Singh

Acadia Pharmaceuticals, a renowned US-based biopharmaceutical company dedicated to the development of treatments for central nervous system disorders, reportedly announced positive outcomes from its Phase 3 HARMONY stu...